Clarity Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Clarity Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$321K	Buy	646 +1	+0.2%	+$443	0.03%	96
2026 Q1	$288K	Hold	645	–	–	0.03%	89
2025 Q4	$292K	Hold	645	–	–	0.03%	90
2025 Q3	$253K	Buy	+645	New	+$270K	0.03%	104
2025 Q2	–	Sell	-442	Closed	-$214K	–	116
2025 Q1	$214K	Buy	+442	New	+$206K	0.02%	100
2024 Q4	–	Sell	-438	Closed	-$204K	–	160
2024 Q3	$204K	Sell	438 -35	-7%	-$16.8K	0.02%	151
2024 Q2	$222K	Buy	+473	New	+$205K	0.03%	116

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Clarity Financial's VRTX Position: Q2 2026 in Review

Clarity Financial increased its Vertex Pharmaceuticals (VRTX) stake by 0.16% in Q2 2026, buying an estimated $443 and bringing the position to 646 shares worth $321K. The position accounts for 0.03% of the portfolio, ranked #96.

Clarity Financial first reported a position in VRTX in Q2 2024 and has held it in 7 quarters since. 981 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Clarity Financial held 646 shares of Vertex Pharmaceuticals worth $321K as of Q2 2026.
Clarity Financial bought 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
Vertex Pharmaceuticals made up 0.03% of Clarity Financial's portfolio in Q2 2026, its #96 holding.
Clarity Financial first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
981 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Clarity Financial's 13F filing for Q2 2026, filed 20 Jul 2026.